Trading Statement: HEPS from continuing and discontinued operations will be between 28% and 25% lower to between 40.3c and 41.9c. The share traded in nearly 3.4x its normal volumes yesterday. JP Morgan has a neutral rating on the stock, (after adjusting expected revenue lower) with a 2140c target price, indicating little upside for the healthcare provider from these levels.